LogicBio Therapeutics (LOGC) Projected to Post Earnings on Tuesday

LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect LogicBio Therapeutics to post earnings of ($0.0419) per share and revenue of $23.31 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:00 PM ET.

LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The business had revenue of $33.60 million during the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Trading Up 0.3%

Shares of LOGC opened at $15.30 on Tuesday. LogicBio Therapeutics has a 52-week low of $7.05 and a 52-week high of $15.41. The business’s fifty day moving average is $14.03 and its 200-day moving average is $9.96. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

LogicBio Therapeutics Company Profile

(Get Free Report)

LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.

LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.

See Also

• Five stocks we like better than LogicBio Therapeutics
• A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
• Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
• Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
• Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.